KRAS and duodenal adenocarcinoma: Kaplan-Meier analysis of survival in duodenal adenocarcinoma showed that TNM stage II or higher (P < 0.01), anatomical location (oral side of Vater; P = 0.03), undifferentiated (P < 0.01), KRAS mutation (P < 0.01), gastric phenotype (P = 0.01), intestinal phenotype (P < 0.01), and PD-L1 status (P < 0.01) significantly influenced patient outcomes (Figures 1–3).